"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

Hims & Hers believes that is where the controversy lies. “We called on the industry and said that they need to change — and ...

Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...

Hims & Hers Health is set to have a commercial air during Super Bowl LIX. It’s already courting controversy, with calls to ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Weight loss drugs, which took the US market by storm, are looking to be a big opportunity for drug makers in India. Several ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...